“Cancers that retain wild type TP53 presumably harbor other clonal alterations that permitted their precursors to bypass p53-mediated growth suppression.” A breakthrough in the study was the ...

Loss of normal p53 function has been associated with resistance to both chemotherapy and radiotherapy. Introduction of wild-type (wt) p53 by means of adenoviral vectors has been shown to inhibit ...

"Cancers that retain wild type TP53 presumably harbor other clonal alterations that permitted their precursors to bypass p53-mediated growth suppression." A breakthrough in the study was the ...

Blocking the MDM2–p53 interaction to reactivate wild-type p53 function is therefore a promising cancer therapeutic strategy, especially in this setting. At Boehringer Ingelheim, we have ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

Once they started searching, scientists found p53 in almost every cancer type. Groups studying p53 and its gene across different model organisms even found this protein in nonmammalian organisms like ...

For endometrial cancer, the adjusted Phase 3 trial design will target p53 wild-type, pMMR tumors, with data expected in mid-2026. U.S. XPOVIO net product revenue is forecasted to grow in 2025 ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...